Barclays Issues Positive Forecast for Omnicell (NASDAQ:OMCL) Stock Price

Omnicell (NASDAQ:OMCL) had its price target hoisted by Barclays from $39.00 to $58.00 in a research note released on Thursday, Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Other equities research analysts have also issued reports about the company. Benchmark restated a “buy” rating and issued a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Wells Fargo & Company raised their target price on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a research note on Saturday, October 19th. Bank of America reiterated a “neutral” rating and issued a $57.00 price objective (up previously from $44.00) on shares of Omnicell in a research report on Thursday. Finally, Craig Hallum boosted their price objective on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Omnicell currently has a consensus rating of “Hold” and a consensus price target of $49.14.

Omnicell Price Performance

Shares of NASDAQ OMCL traded down $0.10 during mid-day trading on Thursday, hitting $48.54. 198,297 shares of the company traded hands, compared to its average volume of 525,856. The company has a current ratio of 1.05, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47. Omnicell has a 1 year low of $25.12 and a 1 year high of $55.74. The business has a 50 day moving average of $43.26 and a two-hundred day moving average of $35.17.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a negative net margin of 1.66% and a positive return on equity of 2.55%. The business had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. During the same period in the prior year, the firm earned $0.29 earnings per share. The firm’s revenue was down 7.4% compared to the same quarter last year. As a group, analysts predict that Omnicell will post 0.64 earnings per share for the current year.

Hedge Funds Weigh In On Omnicell

Several institutional investors have recently added to or reduced their stakes in OMCL. Arizona State Retirement System raised its stake in shares of Omnicell by 2.9% in the second quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock valued at $348,000 after acquiring an additional 357 shares during the last quarter. Texas Permanent School Fund Corp grew its holdings in shares of Omnicell by 1.2% during the first quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock worth $1,158,000 after purchasing an additional 479 shares during the last quarter. Diversified Trust Co raised its holdings in shares of Omnicell by 3.3% in the second quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock valued at $416,000 after buying an additional 494 shares during the last quarter. GAMMA Investing LLC increased its position in Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after acquiring an additional 553 shares in the last quarter. Finally, Louisiana State Employees Retirement System boosted its position in Omnicell by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock valued at $625,000 after buying an additional 600 shares during the last quarter. 97.70% of the stock is owned by institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.